TrialCell reports. Medicine2024

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.

Nima Sharifi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.